Greenwich LifeSciences
Clinical-stage biopharmaceutical company developing a peptide-based cancer immunotherapy combining a HER2/neu-derived peptide with an immunoadjuvant. Conducting a Fast Track designated Phase III randomized, double-blind multicenter trial (Flamingo-01) across ~150 sites to evaluate prevention of breast cancer recurrence in HER2-positive patients; prior clinical program includes three Phase I trials and one Phase IIb trial with 146 treated patients.
Industries
biopharma
biotechnology
life-science
Nr. of Employees
small (1-50)
Greenwich LifeSciences
Stafford, Texas, United States, North America
Products
Peptide-based cancer immunotherapy (peptide + immunoadjuvant)
A short HER2/neu-derived peptide antigen administered intradermally with an immunoadjuvant to stimulate antigen-presenting cells and elicit CD8+ cytotoxic T cell responses against HER2-expressing tumor cells.
Peptide-based cancer immunotherapy (peptide + immunoadjuvant)
A short HER2/neu-derived peptide antigen administered intradermally with an immunoadjuvant to stimulate antigen-presenting cells and elicit CD8+ cytotoxic T cell responses against HER2-expressing tumor cells.
Expertise Areas
- Clinical trial management
- Peptide immunotherapy development
- Immuno-oncology and immune monitoring
- Clinical data management and biostatistics
Key Technologies
- Peptide-based vaccine immunotherapy
- Immunoadjuvant co-administration (GM-CSF)
- Dimer binding assays for antigen-specific CTLs
- Delayed-type hypersensitivity (DTH) skin testing